A special issue dedicated to the 2021 meeting of the French Society for Nanomedicine.
GARANGER, Elisabeth
Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences
Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences
MIGNET, Nathalie
Unité de Technologies Chimiques et Biologiques pour la Santé [UTCBS - UM 4 (UMR 8258 / U1267)]
See more >
Unité de Technologies Chimiques et Biologiques pour la Santé [UTCBS - UM 4 (UMR 8258 / U1267)]
GARANGER, Elisabeth
Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences
Laboratoire de Chimie des Polymères Organiques [LCPO]
Team 3 LCPO : Polymer Self-Assembly & Life Sciences
MIGNET, Nathalie
Unité de Technologies Chimiques et Biologiques pour la Santé [UTCBS - UM 4 (UMR 8258 / U1267)]
Unité de Technologies Chimiques et Biologiques pour la Santé [UTCBS - UM 4 (UMR 8258 / U1267)]
SANCEY, Lucie
Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) [IAB]
< Reduce
Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) [IAB]
Language
EN
Article de revue
This item was published in
International Journal of Pharmaceutics. 2023-05-10, vol. 638, p. 122928
English Abstract
The field of nanomedicine has reached a milestone since the approval of Patisiran, the first ever-approved siRNA drug designed to treat transthyretin (TTR) amyloidosis. The great success of Corminaty and Spikevax messenger ...Read more >
The field of nanomedicine has reached a milestone since the approval of Patisiran, the first ever-approved siRNA drug designed to treat transthyretin (TTR) amyloidosis. The great success of Corminaty and Spikevax messenger RNA (mRNA)-based vaccines against COVID-19 has really brought to light how potent nanomedicine could be. Today, stakeholders are getting more confident in the benefits of nanomedicine for diagnosis, treatment, vaccination, and research related to different types of diseases. For the years to come, it is becoming clear that we need a multidisciplinary approach to achieve a rational design of nanomedicine. Impelling the meeting and discussions of academic and private actors from different disciplines is one of the goals of the French Society for Nanomedicine (SFNano).Read less <
English Keywords
Nanomedicine
Drug Delivery Systems
mRNA-based vaccines
siRNA drugs